US Patent

US12310978 — Composition and method for oral delivery of androgen prodrugs

Method of Use · Assigned to Lipocine Inc · Expires 2039-02-21 · 13y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects a method for administering oral testosterone undecanoate compositions to hypogonadal males without the fat content of a meal affecting bioavailability.

USPTO Abstract

Provided oral testosterone undecanoate compositions can be administered to hypogonadal males with a meal without the fat content of the meal substantially effecting bioavailability.

Drugs covered by this patent

Aveed (TESTOSTERONE UNDECANOATE) · Marius

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-4194`	—	Aveed

Patent Metadata

Patent number: US12310978
Jurisdiction: US
Classification: Method of Use
Expires: 2039-02-21
Drug substance claim: No
Drug product claim: No
Assignee: Lipocine Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.